Liver enzyme CYP2D6 gene and tardive dyskinesia.

Background: Tardive dyskinesia (TD) is an iatrogenic involuntary movement disorder occurring after extended antipsychotic use with unclear pathogenesis. CYP2D6 is a liver enzyme involved in antipsychotic metabolism and a well-studied gene candidate for TD. Materials & methods: We tested predicted CYP2D6 metabolizer phenotype with TD occurrence and severity in our two samples of European chronic schizophrenia patients (total n = 198, of which 82 had TD). Results: TD occurrence were associated with extreme metabolizer phenotype, controlling for age and sex (p = 0.012). In other words, individuals with either increased and no CYP2D6 activity were at higher risk of having TD. Conclusion: Unlike most previous findings, TD occurrence may be associated with both extremes of CYP2D6 metabolic activity rather than solely for poor metabolizers.

Citation

Justin Y Lu, Arun K Tiwari, Natalie Freeman, Gwyneth C Zai, Vincenzo de Luca, Daniel J Müller, Maria Tampakeras, Deanna Herbert, Heather Emmerson, Sheraz Y Cheema, Nicole King, Aristotle N Voineskos, Steven G Potkin, Jeffrey A Lieberman, Herbert Y Meltzer, Gary Remington, James L Kennedy, Clement C Zai. Liver enzyme CYP2D6 gene and tardive dyskinesia. Pharmacogenomics. 2020 Oct;21(15):1065-1072

Mesh Tags

Substances

PMID: 32969762

search → result